The first patient has been dosed in a Phase 2 trial of BGE-102, an oral pill built on human aging research, aimed at preserving vision.
Link as first comment.
@longevitytech.bsky.social
@longevitytech.bsky.social
@longevitytech.bsky.socialThe first patient has been dosed in a Phase 2 trial of BGE-102, an oral pill built on human aging research, aimed at preserving vision.
Link as first comment.